A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Men with metastatic castration-resistant prostate cancer (mCRPC) have limited treatment options after progressing on hormonal therapy and chemotherapy. Here, we evaluate the safety and efficacy of atezolizumab (anti–PD-L1) + radium-223 dichloride (radium-223) in men with mCRPC. PATIENTS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Fong, Lawrence, Morris, Michael J., Sartor, Oliver, Higano, Celestia S., Pagliaro, Lance, Alva, Ajjai, Appleman, Leonard J., Tan, Winston, Vaishampayan, Ulka, Porcu, Raphaelle, Tayama, Darren, Kadel, Edward E., Yuen, Kobe C., Datye, Asim, Armstrong, Andrew J., Petrylak, Daniel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974420/
https://www.ncbi.nlm.nih.gov/pubmed/34108181
http://dx.doi.org/10.1158/1078-0432.CCR-21-0063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974420/
https://www.ncbi.nlm.nih.gov/pubmed/34108181
http://dx.doi.org/10.1158/1078-0432.CCR-21-0063

Ejemplares similares